Is Rucaparib on Medicare? Latest policy

Rucaparib (Rucaparib), as an innovative PARP inhibitor, has been approved for multiple indications globally, but it is still waiting to be launched in the domestic market. As of 2025, rucapanib has not yet been approved for marketing in China, and therefore cannot be included in the domestic medical insurance reimbursement system. If patients need to use the drug in China, they can usually only obtain the original drug through overseas import channels and bear high economic costs. This limits its clinical use to a certain extent, especially in patients with advanced or refractory tumors.

From the perspective of medical insurance policy, the inclusion of drugs in the reimbursement system usually requires approval by the State Food and Drug Administration for listing, and completion of drug price negotiations and clinical efficacy evaluation. Since rucapanib is an innovative targeted drug with a relatively high price, its cost-effectiveness and clinical economic evaluation are important references for policy department review. If domestic patients hope to receive support through medical insurance, they still need to wait for the drug to be launched and the subsequent results of medical insurance negotiations. At the same time, overseas clinical data and experience show that rucapanib has obvious efficacy in patients with BRCA gene mutations, especially those who have received multiple lines of treatment or are at risk of drug resistance. It can significantly delay disease progression.

In domestic clinical practice, doctors need to comprehensively consider drug accessibility, patients' financial affordability, and genetic testing results when formulating treatment plans for patients. Before rucapani is included in domestic medical insurance, if patients choose this drug, they need to fully understand the cost and potential risks of treatment, and use it rationally under the guidance of a professional doctor. With the launch of the drug and the accumulation of clinical data, rucapanib is expected to enter the medical insurance system in the future, providing domestic patients with more economical and convenient treatment options.

Reference materials:https://www.drugs.com/mtm/rucaparib.html